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RESEARCH ARTICLE
EFA6 proteins regulate lumen formation through α-actinin 1
Julie Milanini1, Racha Fayad1, Mariagrazia Partisani1, Patrick Lecine2,*, Jean-Paul Borg2, Michel Franco1 and
Frédéric Luton1,‡
ABSTRACT
A key step of epithelial morphogenesis is the creation of the lumen.
Luminogenesis by hollowing proceeds through the fusion of apical
vesicles at cell–cell contacts. The small nascent lumens grow through
extension, coalescence and enlargement, coordinated with cell
division, to give rise to a single central lumen. Here, by using
MDCK cells grown in 3D-culture, we show that EFA6A (also known as
PSD) participates in luminogenesis. EFA6A recruits α-actinin 1
(ACTN1) through direct binding. In polarized cells, ACTN1 was found
to be enriched at the tight junction where it acts as a primary effector of
EFA6A for normal luminogenesis. Both proteins are essential for the
lumen extension and enlargement, where they mediate their effect by
regulating the cortical acto-myosin contractility. Finally, ACTN1 was
also found to act as an effector for the isoform EFA6B (also known as
PSD4) in the human mammary tumoral MCF7 cell line. EFA6B
restored the glandular morphology of this tumoral cell line in an
ACTN1-dependent manner. Thus, we identified new regulators of
cyst luminogenesis essential for the proper maturation of a newly-
formed lumen into a single central lumen.
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INTRODUCTION
During organogenesis, the coordinated establishment of the apico-
basal polarity with the de novo formation of an apical luminal space
is fundamental to the emergence of the different types of epithelia.
In adult organisms, the aptitude of the internal organs, which are
lined with epithelial tissues, to ensure specific functions relies on the
preservation of these characteristics. The failure in doing so is
associated with a large variety of diseases (Blasky et al., 2015; Datta
et al., 2011; Sigurbjörnsdóttir et al., 2014). In particular, these
features are often compromised in carcinomas and tumors are
formed of non-polarized cell aggregates incapable of collectively
organizing a lumen (Martin-Belmonte and Perez-Moreno, 2011;
Tanos and Rodriguez-Boulan, 2008; Wang et al., 2012). However,
compelling tumoral cells to maintain their normal epithelial
phenotype can help them override the power of oncogenes
(DuFort et al., 2011; Weaver et al., 1997). Thus, it is important
to decipher the molecular programs that instruct epithelial cells to
collectively organize around lumens in order to maintain their
physiological homeostasis.
For most epithelial tissues, the de novo formation of a lumen is
generated by hollowing. In this process, apical vesicles are delivered
to a focal point of the cell–cell contact named the apical membrane
initiation site (AMIS) to give rise to the apical plasma membrane
and a facing hollow cavity. The nascent lumen appears first as a
closed elongated space named the pre-apical patch (PAP), which is
limited by tight junctions. The PAP will then open and expand
through a combination of events: the delivery of vesicular
membranes, the repulsion of the apposed membrane by highly
charged molecules, the increase of hydrostatic pressure, the
coalescence of mini-lumens and, eventually, expansion through
cell division. This process is closely synchronized with a profound
rearrangement of the actin cytoskeleton into discrete structures
essential for the attachment of structural and signaling apical
proteins. These proteins will then yield a scaffold to shape the lumen
and form an acto-myosin ring in support of the circumferential
apical junctional complexes (AJCs), which are made of adherens
junctions (AJs) and the apical tight junctions (TJs) that outline the
luminal space (Datta et al., 2011; Sigurbjörnsdóttir et al., 2014). The
organization and functions of the acto-myosin ring attached to the
AJ have been extensively studied (Arnold et al., 2017; Braga, 2016;
Grikscheit and Grosse, 2016; Lecuit and Yap, 2015); however, far
less is known about the actin cytoskeleton associated to the TJ.
Nevertheless, it is likely that both structures are somehow
intermingled within the so-called apical perijunctional acto-
myosin ring (PAMR) (Ebrahim et al., 2013; Sluysmans et al.,
2017). The PAMR is described as a sarcomeric-like belt made of F-
actin bundles containing myosin-II, which confers contractile
properties, and bundling proteins, such as the non-muscle α-
actinins, which stiffen the structure. The balance of both activities is
believed to determine the flexibility of this belt, its
mechanosensitivity and the tension forces exerted on the cell
surface (Foley and Young, 2014; Martin and Goldstein, 2014;
Murrell et al., 2015; Röper, 2015). The existence of a central apical
acto-myosin network with radial contractility has also been reported
(Coravos and Martin, 2016).
The α-actinin (ACTN) family comprises four members, the
muscle ACTN2 and ACTN3, and the non-muscle ACTN1 and
ACTN4, which are expressed in most other cell types. They share a
common primary structure with a N-terminal actin-binding domain
(ABD) and a C-terminal calmodulin-like domain (CAMD)
separated by a central repeat of four spectrin-like domains
(spectrin repeats domain; SRD). ACTN molecules form
antiparallel dimers through their rigid SRD allowing for the cross-
linking of actin filaments by the ABD positioned on either end. In
comparison with the filamin proteins, which orthogonally cross-
link actin filaments, non-muscle ACTNs form linear F-actin
bundles, which increase the stiffness (Jahed et al., 2014; Stossel
et al., 2001). They are believed to contribute to myosin-II-driven
contractility by facilitating force transmission (Le Clainche andReceived 3 August 2017; Accepted 11 December 2017
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Carlier, 2008). ACTNs also act as a mechanical linker between actin
filaments and cell–cell and cell–extracellular matrix (ECM)
adhesion complexes. Besides its structural roles, ACTNs could
also serve to couple actin nucleation to assembly at cell–cell
contacts (Tang and Brieher, 2012) and contribute to the maturation
of cell–ECM focal adhesion by transmitting mechanical forces
(Iskratsch et al., 2014; Jahed et al., 2014; Parsons et al., 2010; Ye
et al., 2014). Both ACTN1 and ACTN4 were found at the apical
acto-myosin ring in association with the AJ (Honda et al., 1998;
Tang and Brieher, 2012), whereas a few studies suggested a link
with the TJ (Chen et al., 2006; Geiger et al., 1979; Nakatsuji et al.,
2008). Nevertheless, the repertoire of ACTN molecules associated
with the various F-actin structures is poorly defined and is made
even more complex by the existence of ACTN1–ACTN4
heterodimers (Foley and Young, 2013). Moreover, it is not
completely clear how ACTNs are recruited to cell–cell contacts.
Thus, much remains to be discovered about the role of ACTNs at the
AJC as well as their role during luminogenesis.
Small G-proteins of the Rho family and their partners are key
regulators in the assembly and maintenance of the PAMR. In
particular, RhoA contributes to the constitution of the contractile
apical acto-myosin array through the localization and activation of
the formin proteins and the activation of the motor protein myosin-II
by the Rho-associated coiled-coil kinase effectors ROCK1 and
ROCK2 (hereafter denoted ROCK) (Arnold et al., 2017; Quiros and
Nusrat, 2014; Sluysmans et al., 2017; Takeichi, 2014). Tension
forces are necessary for the establishment and functioning of the
AJC, as they support the changes in cell shape occurring during
epithelial morphogenesis (Coravos et al., 2017; Lecuit and Yap,
2015; Takeichi, 2014). However, how contractility and its regulators
are impacting epithelial cell luminogenesis is an issue of ongoing
debate.
Another small G-protein that regulates the cortical cytoskeleton is
the ADP ribosylation factor 6 (Arf6). It plays a pivotal role in a wide
variety of cellular events including cell surface trafficking,
phagocytosis, cell–cell adhesion, and tumor cell migration and
invasion (D’Souza-Schorey and Chavrier, 2006; Gillingham and
Munro, 2007; Jaworski, 2007; Sabe et al., 2009; Schweitzer et al.,
2011). In epithelial cells, Arf6 was initially shown to regulate
vesicular trafficking to the apical pole of the cell (Altschuler et al.,
1999) and later to impact the turnover of the AJ (Palacios et al.,
2001, 2002, 2005), the establishment of the TJ (Klein et al., 2008;
Luton et al., 2004), cyst morphogenesis (Tushir et al., 2010) and
HGF-induced tubulogenesis (Tushir and D’Souza-Schorey, 2007).
Consistent with these observations, the exchange factor for Arf6
(EFA6; also known as PSD) was found to be enriched at the apical
pole and at the TJ in fully polarized MDCK cells (Luton et al.,
2004). During early epithelial polarization, EFA6 is recruited to the
cell–cell contact in a manner that is dependent on E-cadherin
engagement, where it contributes to the formation of the TJ by
stabilizing the apical acto-myosin ring (Théard et al., 2010).
Expression of EFA6B (also known as PSD4) in the mammary
tumoral MCF7 cell line restored a normal glandular phenotype, with
the formation of lumens delineated by TJs (Zangari et al., 2014).
Conversely, knockdown of EFA6B expression drives various
mammary cell lines into epithelial-to-mesenchymal transition
(Zangari et al., 2014). In breast cancer patients, the loss of
EF6AB expression is associated with the claudin-low subtype
characterized by the loss of expression of all the TJ components and
a poor prognosis (Zangari et al., 2014).
The EFA6 family consists of four isoforms (EFA6A–EFA6D;
EFA6C is also known as PSD2, and EFA6D as PSD3) sharing a
general structure that comprises a variable N-terminal domain, a
catalytic Sec7 domain bearing the nucleotide exchange activity, a
PH domain responsible for their plasma membrane localization and
a conserved C-terminal region involved in actin cytoskeleton
rearrangement (Derrien et al., 2002; Franco et al., 1999; Sakagami,
2008; Sironi et al., 2009). In a previous study, we found that
mutations that abolish the nucleotide exchange activity or delete the
C-terminal domain abrogated the stimulatory effects of EFA6,
indicating that both Arf6 activation and the C-terminal domain
are necessary for epithelial polarization (Luton et al., 2004).
In addition, complementation experiments demonstrated a finely
tuned cooperation between the two signaling pathways associated
with the activated Arf6 and with the EFA6 C-terminus (Klein et al.,
2008).
In this study, we aimed to determine the signaling pathway
associated to EFA6 C-terminus that contributes to its action on
epithelial morphogenesis. Our data showed that: (1) ACTN1 is a
direct partner of EFA6AC-terminal domain, (2) EFA6A is a crucial
regulator of luminogenesis for which ACTN1 is the major effector,
(3) together, they stimulate the formation and enlargement of a
single lumen with a proper round shape, (4) they act by regulating
cortical acto-myosin contractility, and finally (5) ACTN1 is also a
partner of the EFA6B isoform in the promotion of lumen formation
in the mammary tumoral cells MCF7.
RESULTS
EFA6A binds directly to ACTN1
Looking for functional partners of EFA6A in epithelial cells, we
performed a two-hybrid screen of an epithelial library using the C-
terminus (Cter) of EFA6A as a bait, and identified ACTN1 as the
major interacting protein. A similar result was found by Sakagami
et al. in a previous screen using a neuronal library (Sakagami et al.,
2007). A pulldown assay was used to confirm that the Cter of
EFA6A could bind exogenously expressed ACTN1–GFP (Fig. 1A).
We then further characterized this interaction by assessing whether
the two proteins could bind directly. We found that both
GST–ACTN1 and GST–ACTN4 could pulldown full-length
His–EFA6A (Fig. 1B), and that the central SRD of ACTN1 binds
directly to His–EFA6A (Fig. 1C). In BHK cells, GFP–EFA6A
co-immunoprecipitated endogenous ACTN1 (Fig. 1D), and Myc–
EFA6A re-localized the endogenous ACTN1 to F-actin-enriched
lamellipodia as well as to the cell surface microspikes induced by
Myc–EFA6A (Fig. 1E; Derrien et al., 2002; Macia et al., 2008). We
conclude that, in vitro, ACTN and EFA6A can bind directly through
their respective spectrin and C-terminal domains, and that, in vivo,
EFA6A can recruit the endogenous ACTN1 to cortical F-actin
structures. In agreement with our previous reports (Luton et al.,
2004; Théard et al., 2010; Zangari et al., 2014), during lumen
formation mRFP–EFA6A was transiently found to be enriched at
the AMIS and the opened PAP before its expression at the apical
surface decreased to the low level found in mature cyst (Fig. S1A).
We also examined the localization of ACTN1 and ACTN4
in polarized cysts formed by MDCK cells. ACTN1–GFP was
diffused within the cytoplasm and enriched at the apex of cell-cell
junctions (Fig. S1A). Colocalization of ACTN1–GFP with occludin
(Fig. 1Fa–a″) indicated its accumulation at the TJ. In contrast,
ACTN4–GFP was not consistently observed at the TJ at above the
level of the GFP control (Fig. S1A; Fig. 1Fc–c″). In addition,
ACTN1–GFPwas found to be enriched at the nascent lumen formed
in between two cells and its surrounding TJ (Fig. 1Fb–b″), whereas
ACTN4–GFP was found on the newly formed luminal membrane
and also was enriched along the cell–cell contact (Fig. 1Fd–d″).
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Later, in mature cysts, ACTN4–GFP appeared to be more enriched
in AJs stained for E-cadherin (Fig. S1B). Given the enrichment of
ACTN1 at the TJ, we focused our study on the importance of its role
as an effector of EFA6.
EFA6A recruits ACTN1 in a regulated manner
EFA6A and ACTN1 are cortical actin regulators and both
partially localize to the TJ in polarized epithelial cells; we thus
investigated the mechanism of their direct interaction. ACTN1
could serve as a receptor to recruit EFA6A to the TJ. However,
EFA6A localization to the plasma membrane was shown to rely
on its phosphatidylinositol 4,5-bisphosphate (PIP2)-specific PH
domain and its capacity to bind to F-actin (Macia et al., 2008).
Furthermore, the EFA6A mutant deleted of its C-terminus, which
no longer binds ACTN1, has been shown to localize at the
plasma membrane in a similar manner to the full-length protein
(Franco et al., 1999; Macia et al., 2008). In contrast, as shown
above (Fig. 1E) ACTN1 was re-localized to Myc–EFA6A-
induced membrane ruffles, suggesting that ACTN1 can be used
as an effector of EFA6A in order to remodel the cortical actin
cytoskeleton.
To further analyze the binding of ACTN1 to EFA6A and its
functional properties in living cells, we ectopically expressed
EFA6A away from the plasma membrane. We fused EFA6A to the
mitochondrial-targeting peptide ActA and determined whether
EFA6A–ActAwas capable of re-localizing the endogenous ACTN1
to the outer membrane of mitochondria, from which it is normally
absent. Since ACTN1 binds to the C-terminal domain of EFA6A,
we first studied the EFA6ACter fused to mRFP and ActA (named
hereafter EFA6ACter–mRFP–ActA). As previously observed by
others, depending on the expression rate and construct used, in cells
transfected with ActA chimeras the mitochondrial network tended
to aggregate around the nucleus (Bubeck et al., 1997; Moeller et al.,
2004; Reinhard et al., 1999; Zhang et al., 2009). Nevertheless, all
constructs localized to the mitochondria as assessed by monitoring
colocalization with the mitochondrial protein Hsp60 (also known as
HSPD1) (Fig. S2A). When expressed in BHK cells, EFA6ACter–
mRFP–ActA localized to the mitochondria (Fig. S2A) and recruited
endogenous ACTN1 (Fig. 2A; magnification in Fig. S2B). In
contrast, the control mRFP–ActA construct, which also localized to
the mitochondria (Fig. S2A), did not recruit ACTN1 (Fig. 2A).
Interestingly, the full-length EFA6A–mRFP–ActA localized to the
mitochondria (Fig. S2A) but did not re-localize ACTN1 (Fig. 2A).
This observation suggests that the Cter was not available for ACTN1
binding in the full-length EFA6A. Our previous work indicates that
EFA6A exists in a closed conformation where the Cter is folded
Fig. 1. EFA6A binds directly to ACTN1. (A) Lysate of MDCK cells expressing ACTN1–GFP was reacted with GST, GST–EFA6A or GST–EFA6ACter prebound to
glutathione–sepharose beads. The top arrowhead points to GST–EFA6A and the bottom arrowhead toGST–EFA6ACter. (B) PurifiedGST, GST–ACTN1 andGST–
ACTN4 prebound to glutathione–sepharose beads were reacted with purified (6xHis)–EFA6A. The asterisk highlights a main purification contaminant. (C) Purified
GST, GST–ABD, GST–SRD and GST–CAMD (fragments of ACTN1) prebound to glutathione–sepharose beads were reacted with purified (6xHis)-EFA6A. In A–C,
the input or whole lysate and bound proteins were analyzed by immunoblotting with the indicated antibodies. (D) GFP or GFP–EFA6A expressed in BHK cells were
immunoprecipitated using an anti-GFP antibody and the co-precipitation of endogenous ACTN1 was assessed by immunoblotting. (E) BHK cells expressing
or not expressingMyc–EFA6Awere processed for immunofluorescence and stained forMyc (blue), F-actin (red) and the endogenousACTN1 (ACTN1endo., green).
Arrowheads point to EFA6A-induced lamellipodia where the endogenous ACTN1 is recruited. (F) MDCK cells expressing ACTN1–GFP (green; a–b″) or ACTN4–
GFP (green; c–d″) were processed for immunofluorescence to label the endogenous occludin (red) in mature or nascent lumens. Scale bars: 10 µm.
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back onto the PH domain, preventing its association with the
C-terminus of β-arrestin1 (denoted β-arrestin1Cter), another
EFA6ACter ligand (Macia et al., 2012). To test whether the
EFA6A–mRFP–ActA was in a locked conformation, we co-
expressed β-arrestin1Cter–GFP with EFA6ACter–mRFP–ActA or
the full-length EFA6A–mRFP–ActA constructs. Similar to what
was observed with ACTN1, β-arrestin1Cter–GFP could only bind to
EFA6ACter–mRFP–ActA (Fig. 2B) indicating that the binding of
ACTN1 to EFA6A is regulated, and requires the release of its
C-terminal domain.
Some F-actin staining was observed colocalized together with
EFA6ACter–mRFP–ActA and the endogenous ACTN1 at the
mitochondria (Fig. 2A; magnification in Fig. S2B). When the cells
were treated with Latrunculin A, F-actin was absent from the
mitochondria whereas the endogenous ACTN1 was still efficiently
recruited by EFA6Cter–ActA (Fig. 2C). Thus, independently of the
Fig. 2. EFA6A recruits ACTN1 in a regulated manner. (A) BHK cells expressing EFA6ACter–mRFP–ActA, mRFP–ActA and EFA6A–mRFP–ActA were
processed for immunofluorescence to label the endogenous ACTN1 and F-actin. In merge images, mRFP is colored red, ACTN1 blue and F-actin green. (B) BHK
cells co-expressing β-arrestin1Cter–GFP (green) with EFA6ACter–mRFP–ActA (red) or with the full-length EFA6A–mRFP–ActA (red) were processed for
immunofluorescence to label the endogenous F-actin (blue). (C) BHK cells expressing EFA6ACter–mRFP–ActA were exposed to Latrunculin A (2 µM) for 2 h.
The cells were processed for immunofluorescence to label the endogenous ACTN1 (green) and F-actin (blue). Scale bars: 10 µm.
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presence of F-actin, EFA6A can directly recruit ACTN1, which in
turn might function as an effector to organize EFA6A-regulated
actin-based structures.
Depletion of ACTN1 inhibits normal EFA6A-induced
luminogenesis
We have previously shown that expression of EFA6A tagged with
the G glycoprotein of the vesicular stomatitis virus (VSV-G) (VSV-
G–EFA6A) stimulates apical polarity development and TJ
formation in MDCK cells (Klein et al., 2008; Luton et al., 2004).
To assess the role of ACTN1 as an effector of EFA6A, we analyzed
the effects of its downregulation in cells grown in a 3D-culture
system in Matrigel. Several siRNAs against ACTN1 were tested for
their efficiency to downregulate its expression (Fig. S3A). ACTN1
knockdown was carried out in MDCK cells in which the expression
of VSV-G–EFA6A is under the control of the tetracycline (Dox)-
repressible transactivator (hereafter denoted MDCK-VSV-G–
EFA6A cells) (Luton et al., 2004). Fig. 3A is a representative
immunoblot analysis of ACTN1 depletion and VSV-G–EFA6A
expression in the presence or absence of doxycycline.
We first examined whether EFA6A overexpression stimulated
epithelial polarity in MDCK cells grown in Matrigel over 3 days.
Cysts of homogenous size (from 4 to 15 cells) were analyzed for the
formation of one or multiple lumens and for their shape. They were
also characterized for extension and expansion. Extension refers to
the opening of the lumen to all the cells of the aggregates, while
expansion refers to the enlargement of the luminal space. Upon
VSV-G–EFA6A expression (−Dox) we observed an increase in the
formation of cysts displaying a single central lumen (SCL). In
addition, the luminal space became more round with an almost
doubling (from 23% to 40%) of the SCL, with it displaying a round
shape upon VSV-G–EFA6A expression (Fig. 3B, shaded bars and
upper right panel). In contrast, depletion of ACTN1 in control
conditions (+Dox) reduced the number of cysts with a SCL and
Fig. 3. Depletion of ACTN1 inhibits normal EFA6A-induced luminogenesis. (A) MDCK cells expressing inducible VSV-G–EFA6Awere transfected with siRNA
directed against ACTN1 (siACTN1; #2225) or with control siRNA (siCt), and were grown without or with doxycycline (Dox) to induce or not the expression of VSV-G–
EFA6A, respectively. At 48 h post transfection, the cells were solubilized in SDS lysis buffer and the expression of the indicated proteins was analyzed by
immunoblotting. The p85 regulatory subunit of PI3K served as a loading control. (B) Left, quantification of the percentage of cell aggregates with a SCL (left y-axis).
Shaded areas indicate the percentage of those SCL aggregates with a round lumen (right y-axis). Results are mean±s.d., n=5. Right, representative images
of the four cell types labeled for the nuclei (blue), apical marker PDX (green) and F-actin (red) are shown. The insets display an image of the same lumens stained for
F-actin (red) and the TJmarker occludin (green). Arrowheads point to the TJs. (C) MDCK cells expressing ACTN1S744–GFPwere transfected with siCt or siACTN1
(#2225). Top panel, the cells were solubilized in SDS lysis buffer and the expression of the indicated proteins analyzed by immunoblotting. Hsp60 served as a
loading control. Bottom panel, quantification of the percentage of aggregates with a SCL. No significant difference was measured. Results are mean±s.d., n=3.
(D)Quantification of the percentage of aggregateswithmultilumens or incomplete lumens for the indicated conditions. Results aremean±s.d., n=5. (E)Quantification
of the percentage of aggregates with mini-lumens for the indicated conditions. Representative images of cells depleted in ACTN1, and expressing or not expressing
VSV-G–EFA6A, labeled for the nuclei (blue), the apical marker PDX (green) and F-actin (red). The insets display an image of the same mini-lumens stained
for F-actin (red) and the TJ marker occludin (green). Arrowheads point to the TJ. *P≤0.05; **P≤0.01; ***P≤0.001 (Student’s t-test). Scale bars: 10 µm.
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severely altered the shape of the lumen such that the lumens adopted
an ‘octopus-like’ shape with a small central opening from which
closed or barely opened luminal extensions reached in between the
cells (Fig. 3B, shaded bars and lower left panel). Depletion ofACTN1
in cells expressing VSV-G–EFA6A also impaired enlargement of the
lumens, although the opening was more visible (Fig. 3B, shaded bars
and bottom right panel). Thus, ACTN1 is required for the stimulatory
effects found for EFA6A on SCL formation and on the rounding of
the luminal space of multicellular cysts. However, in all conditions,
the cells remained well polarized as indicated by the correct
localization of the apical podocalyxin (PDX; also known as
PODXL) and basolateral (E-cadherin) markers (Fig. S3B), and by
the basal positioning of the nuclei, the general F-actin organization
and the apical assembly of the TJ (Fig. 3B). To confirm that the
phenotypes induced by the siRNA against ACTN1 (siACTN1) were
due to ACTN1 depletion we carried out a rescue experiment. MDCK
cells expressing anACTN1–GFPwhich is insensitive to the siACTN1
(ACTN1S744–GFP) did not display any defect in lumen formation
upon depletion of the endogenous ACTN1 (Fig. 3C).
The loss of cysts with SCLs in the ACTN1-depleted cells was
counterbalanced by an increase of cell aggregates with multiple
lumens and others with incomplete extension to all of the cells
(Fig. 3D, see Materials and Methods). In both cases, the lumens
displayed the distorted octopus-like shape. The extension defect was
further reflected by a strong increase in the number of aggregates
displaying multiple lumens that only opened in between two cells
(hereafter called mini-lumens) that were often blocked at the PAP
stage with no visible opening (Fig. 3E), which suggests that ACTN1
depletion might favor the early formation of an initial lumen. VSV-
G–EFA6A expression did not significantly alter the phenotypic
changes imposed upon ACTN1-depletion; however, it stimulated
the enlargement and rounding of the mini-lumens blocked at the
two-cell stage (Fig. 3E, right panel). Thus, as opposed towhat is seen
for mature lumens, EFA6A can stimulate the volumetric enlargement
of nascent mini-lumens in an ACTN1-independent manner. Taken
together, these observations suggest that ACTN1 is dispensable for
the formation of the initial lumen in between two cells but is required
later on for its extension and enlargement (see Discussion section for
further comments). In summary, depletion of ACTN1 blocked both
the effects of VSV-G–EFA6A on luminogenesis, that is, the
formation of fully extended SCL and its expansion as regular round
lumen. This suggests that ACTN1 acts as an effector downstream of
EFA6A that is important for luminogenesis.
ACTN1 acts as an effector of EFA6A to promote normal
luminogenesis
If EFA6A controls luminogenesis and ACTN1 acts as an effector,
then EFA6A depletion should hamper luminogenesis, and when
combined with ACTN1 depletion there should have no additional
effect. MDCK-VSV-G–EFA6A cells grown in the absence or
presence of doxycycline were submitted to siRNA against EFA6A
(siEFA6A)-, siACTN1- or simultaneous siEFA6A- and siACTN1-
mediated depletion. The efficient knockdown of the indicated
proteins and the induction of the expression of VSV-G–EFA6A
were analyzed by immunoblotting (Fig. 4A; Fig. S4).
Depletion of the endogenous EFA6A was accompanied by a
reduction in the amount of cell aggregates with a SCL
demonstrating that EFA6A is required for luminogenesis
(Fig. 4B). Expression of the exogenous human VSV-G–EFA6A,
which is insensitive to the canine-specific siRNA, rescued the
normal phenotype, thus controlling for the specificity of EFA6A
knockdown (Fig. 4B). As shown in Fig. 3, ACTN1 depletion
hampered luminogenesis and blocked the VSV-G–EFA6A
stimulation. However, ACTN1 depletion did not have any
additional effect when the endogenous EFA6A was knocked
down (Fig. 4B). In addition, the exogenous expression of VSV-G–
EFA6A in the double knockdown cells could not rescue the normal
phenotype (Fig. 4B). In addition, we analyzed the consequences on
the lumen formation of expressing a mutant of EFA6A deleted of its
C-terminus (EFA6AΔC), which contains the ACTN1-binding site.
Expression of VSV-G–EFA6AΔC impaired normal luminogenesis
and caused the formation of lumens with an octopus-like shape
(Fig. 4C). Although the C-terminus of EFA6A likely interacts with
other molecules, it is important to note that its truncation generated
lumens with shapes that were similar to those observed in ACTN1-
depleted cells. Taken together, these observations indicate that
EFA6A mediates luminogenesis in MDCK cells and that ACTN1 is
a crucial effector for this process.
ACTN1 is an effector of EFA6B for luminogenesis induction in
MCF7 breast cancer cells
We have reported that the EFA6B isoform is an antagonist of breast
cancer development (Zangari et al., 2014). Tumoral MCF7 cells
grown in 3D-culture systems form compact aggregates with no
lumen (Han et al., 2010; Kenny et al., 2007). The exogenous
expression of VSV-G–EFA6B in the tumoral MCF7 cells restores
an epithelial phenotype characterized by the appearance of
aggregates with extended lumens (although not often a SCL),
delineated by functional TJs (Zangari et al., 2014). Thus, we asked
whether ACTN1 was required downstream of EFA6B to contribute
to luminogenesis in MCF7 cells.
We first verified that ACTN1 could also bind to the EFA6B
isoform (Fig. S5). Next, we analyzed the effect of ACTN1 depletion
in both control MCF7 and MCF7-VSV-G–EFA6B cells grown in
Matrigel. An immunoblot analysis demonstrated the efficient
knockdown of ACTN1 in both cell lines (Fig. 5A). We quantified
the number of aggregates with extended lumens opened to at least
four cells, as opposed to mini-lumens opened in between only two
cells. As previously reported, MCF7 control cells do not form cysts
with lumens (Han et al., 2010; Kenny et al., 2007; Zangari et al.,
2014), whereas exogenous expression of VSV-G–EFA6B induced
the formation of cysts with extended lumens (Fig. 5B; Zangari et al.,
2014). We observed that ACTN1 depletion blocked the formation of
extended lumens induced by EFA6B indicating that, in MCF7 cells,
ACTN1 is also a crucial effector of EFA6B-induced lumen
formation (Fig. 5B). In addition, although control MCF7 cell
aggregates did not form extended lumens, in ∼20% of the
aggregates one or several mini-lumens were observed (Fig. 5C,D).
Upon ACTN1 depletion, the number of these mini-lumens
increased in both the VSV-G–EFA6B-expressing and non-
expressing MCF7 cell lines. However, in VSV-G–EFA6B-
expressing cells aggregates the luminal space was enlarged while
inMCF7 controls cells themini-lumenswere seen as PAPs (Fig. 5C,D).
Thus, similar to what we had observed in MDCK cells, ACTN1
depletion facilitates the initial lumen formation in between two cells but
then hampers both extension and enlargement.
EFA6AandACTN1control apical contractility contributing to
luminogenesis
The PAMR and ventral stress fibers (SFs) are sarcomere-like actin-
based structures capable of contractility that have been implicated in
epithelial morphogenesis. Contractile actin bundles are formed by
aligned fibers cross-linked by a periodic distribution of ACTNs that
alternates with myosin-II (Burridge andWittchen, 2013; Sluysmans
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et al., 2017). RhoA and its effectors (ROCK and mDia1) have been
recognized as major regulators of the contractile properties of the
acto-myosin cytoskeletons (Arnold et al., 2017; Quiros and Nusrat,
2014; Sluysmans et al., 2017; Takeichi, 2014). Thus, we tested the
possibility that EFA6A and ACTN1 regulate luminogenesis by
contributing to the PAMR contractility. First, we used an antibody
directed against the phosphorylated regulatory myosin light chain 2
(pMLC, also known as MYL2) as a proxy to evaluate the tension
forces in response to modulating EFA6A and ACTN1 expression.
Fig. 6B shows a representative immunoblot analysis of ACTN1
depletion and VSV-G–EFA6A expression in the presence or
absence of doxycycline. In control cells, the pMLC staining
appeared as small intracellular dots, as well as larger dots located in
proximity to the apical membrane. Under conditions of EFA6A or
ACTN1 depletion, this apical staining disappeared and the pMLC
distribution became more diffuse. Upon VSV-G–EFA6A
expression the proportion of apical pMLC was increased and its
staining was evenly distributed all around the luminal cortex. In
ACTN1-depleted cells, the VSV-G–EFA6A-induced apical
accumulation of pMLC was abrogated (Fig. 6A). These results
suggest that EFA6A can modulate the apical tension forces in an
ACTN1-dependent manner.
We investigated the contribution of ACTN1 by first analyzing the
effect of its depletion on the RhoA-stimulated ventral SFs inMDCK
cells by expressing the N-terminal Myc-tagged constitutively active
mutant of RhoA (Myc–RhoAV14) under the control of the
inducible Tet-off system. The levels of expression of the proteins
in different conditions were analyzed by immunoblotting (Fig. 6C).
We monitored the Myc–RhoAV14-induced SF contractility by
immunofluorescence. We looked at the F-actin organization and the
Fig. 4. ACTN1 acts as an effector of EFA6A to promote normal luminogenesis. (A) MDCK cells expressing inducible VSV-G–EFA6Awere transfected with siRNA
control (siCt), siRNA directed against ACTN1 (siACTN1; #2225) or EFA6A (siEFA6A; #2661), or both siACTN1 and siEFA6A, and then grown without or with
doxycycline (Dox) to induce or not the expression of VSV-G–EFA6A, respectively. At 48 h post transfection the cells were solubilized in SDS lysis buffer and the
expression of the indicated proteins analyzed by immunoblotting. Hsp60 served as a loading control. (B) Quantification of the percentage of cell aggregates with a SCL.
Results aremean±s.d., n=4. (C)MDCKcells expressing inducibleVSV-G–EFA6AΔCwere grownwith orwithout Dox. Top panel, at 48 h post transfection the cellswere
solubilized in SDS lysis buffer and the expression of VSV-G–EFA6AΔC analyzed by immunoblotting. Hsp60 served as a loading control. Middle panel, representative
images of cell aggregates grown with or without Dox labeled for the nuclei (blue), apical marker PDX (green) and F-actin (red). Bottom panel. quantification of the
percentage of cell aggregates with a SCL. Results are mean±s.d., n=3. *P≤0.05; **P≤0.01; ***P≤0.001; N.S., not significant (Student’s t-test). Scale bars: 10 µm.
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contractility status by following the distribution of pMLC and
paxillin, a marker of the focal adhesions (Fig. 6D). As expected, the
expression of Myc–RhoAV14 (−Dox) stimulated the formation of
SFs that appeared as thick bundles of parallel F-actin going across
the whole cell cluster (Fig. 6Db). In Myc–RhoAV14-expressing
cells, pMLC was redistributed all along the SFs (Fig. 6Db′) while in
control cells pMLC was enriched at the periphery of the cell cluster
and excluded from cell–cell contacts (Fig. 6Da′). Concomitantly,
paxillin was re-localized to the periphery of the cell cluster mostly
decorating the focal adhesions at the extremity of the SF (Fig. 6Db″).
As previously observed by others (Oakes et al., 2012), depletion of
ACTN1 in control cells (+Dox) led to the loss of bundles or
shortening of radial F-actin bundles resembling transverse arcs
(Fig. 6Dc). These structures were stained for pMLC, which remained
absent from cell–cell contacts (Fig. 6Dc′). The paxillin signal
increased but was still homogeneously distributed within each cell of
the cluster similar to what was seen in control cells (Fig. 6Dc″).
Depletion of ACTN1 blocked the effects of Myc–RhoAV14, leading
to cells displaying a phenotype that was comparable to that of the
control cells with respect to all three markers (Fig. 6Dd–d″). We
conclude that ACTN1 can balance the contractility status of RhoA-
dependent SFs in MDCK cells.
Interfering with the RhoA–ROCK–myosin-II contractility
pathway has been shown to alter luminogenesis in MDCK cells
(Ferrari et al., 2008; Kim et al., 2015; Rodríguez-Fraticelli et al.,
2012). In particular, under permissive conditions, the
constitutively active RhoAV14 mutant blocks the initial step of
lumen formation (Ferrari et al., 2008). We thus asked whether
ACTN1 depletion could prevent the Myc–RhoAV14 inhibitory
effect on luminogenesis. In our 3D cell culture conditions, Myc–
RhoAV14 expression abrogated lumen formation. The cells
became round and loosely attached, forming aggregates almost
exclusively without lumens and that displayed an inverted
polarity, as judged by the peripheral localization of the apical
PDX marker (Fig. 6E,F). ACTN1 depletion partially rescued the
formation of lumens (Fig. 6E). We observed aggregates with
multilumens or incomplete lumen formation, essentially as mini-
lumens (Fig. 6E). The cells adopted a more cuboidal shape and
formed more-compact aggregates (Fig. 6F). These results suggest
that the knockdown of ACTN1 acts to reduce the strong
Fig. 5. ACTN1 is an effector of EFA6B that acts to induce luminogenesis in the MCF7 breast cancer cell line. (A) Control and VSV-G–EFA6B-expressing
MCF7 cells were transfected with siRNA control (siCt) or siRNA directed against ACTN1 (siACTN1). At 48 h post transfection the cells were solubilized in
SDS lysis buffer and the expression of the indicated proteins analyzed by immunoblotting. Actin served as a loading control. (B) Quantification of the percentage of
the indicated cell aggregates with extended lumens. (C) Quantification of the percentage of the indicated cell aggregates with mini-lumens. Results in B and C
are mean±s.d., n=3. *P≤0.05; ***P≤0.001 (Student’s t-test). (D) Representative images of cells depleted or not for ACTN1 and expressing or not expressing
VSV-G–EFA6B. The cell aggregates were processed for immunofluorescence by labeling cytoskeletal F-actin with fluorescent phalloidin. Arrowheads point to
PAPs. Scale bars: 10 µm.
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Fig. 6. EFA6A and ACTN1 control apical contractility, thereby contributing to luminogenesis. (A,B) MDCK cells expressing inducible VSV-G–EFA6Awere
transfected with siRNA control (siCt), or siRNA directed against ACTN1 (siACTN1; #2225) or EFA6A (siEFA6A; #2661) and then grown without or with doxycycline
(Dox) to induce or not the expression of VSV-G–EFA6A, respectively. (A) Representative images of the aggregates labeled for pMLC, F-actin and the nuclei. Top
panels, pMLC staining alone. Bottom panels show the corresponding merged images; pMLC is colored in green, F-actin in red and the nuclei in blue. Scale bars: 10
µm. (B) At 48 h post transfection the cells were solubilized in SDS lysis buffer and the expression of the indicated proteins analyzed by immunoblotting. Hsp60 served
as a loading control. (C) MDCK cells expressing inducible Myc–RhoAV14 were transfected with siCt or siACTN1 (#2225) and grown with or without doxycycline. At
48 h post transfection the cells were solubilized in SDS lysis buffer and the expression of the indicated proteins was analyzed by immunoblotting. Hsp60 served as a
loading control. (D) MDCK cells expressing inducible Myc–RhoAV14 were transfected with siCt or siACTN1 (#2225) and grown on coverslips with or without
doxycycline. At 48 h post transfection the cells were processed for immunofluorescence and labeled for F-actin (a–d), pMLC (a′–d′) and the focal adhesion protein
paxillin (a″–d″). Scale bars: 20 µm. (E) MDCK cells expressing inducible Myc-RhoAV14 were transfected with siCt or siACTN1 (#2225), and grown with or without
doxycycline inMatrigel.Quantification of the indicated cell aggregates forSCLs,multilumens and incomplete lumens or no lumen is reported in the bar graph.Results
aremean±s.d.,n=3. **P≤0.01; ***P≤0.001 (Student’s t-test). (F)Representative imagesMDCKcellswith inducibleMyc–RhoAV14depletedor not for ACTN1 (#2225)
and grown for 4 days inMatrigel with or without doxycycline. The cell aggregateswere processed for immunofluorescence and labeled for the nuclei (blue), the apical
marker PDX (green) and the F-actin (red). Arrowheads point to PAPs and mini-lumens. Scale bars: 10 µm.
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contractility imposed by Myc–RhoAV14, thus allowing the
initiation of lumen formation. This is in agreement with
previous studies that show that reduction of the myosin-II
contractility stimulates the initial early step of lumen opening at
the two-cell stage (Ferrari et al., 2008; Rodríguez-Fraticelli et al.,
2012). However, the extension and enlargement of the lumens,
which we demonstrate to be dependent on ACTN1, were both still
compromised upon reduction of contractility induced by ACTN1
depletion. Thus, our findings support a model whereby the initial
stage of the lumen formation is facilitated by the absence of ACTN1,
followed by lumen maturation, which is ACTN1 dependent.
Taken together, our data suggest that EFA6A and its effector
ACTN1 contribute to SCL formation through the regulation of the
cell surface tension forces within the cell aggregate.
DISCUSSION
In this study, we aimed to define the role of EFA6, a regulator of
epithelial polarization, in lumen formation by using a 3D epithelial
cell culture system. Given the importance of the reorganization of
the actin cytoskeleton during cystogenesis, we were particularly
interested in deciphering the signaling pathway associated with the
EFA6 C-terminal domain that is capable of remodeling the cortical
actin independently of EFA6 GEF activity.
Searching for partners of EFA6ACter, we find that EFA6A binds
directly to the non-muscular ACTN member ACTN1. We
characterized this interaction in living cells by using a
mitochondrial-targeting system, and observed that it is likely
regulated by the structural conformation of the EFA6AC-terminus.
This observation confirms our previous results obtained with
another EFA6Cter ligand, β-arrestin1 (Macia et al., 2012), and
implies the existence of a common regulatory mechanism whereby
binding to EFA6ACter requires an opening signal. A possible
candidate for mediating this signal is Arf6-GTP, the product of
EFA6A Sec7-dependent nucleotide exchange activity. ARNO (also
known as CYTH2), another Sec7 family guanine nucleotide
exchange factor for Arf1, was shown to adopt an auto-inhibited
conformation where its short C-terminus downstream of the
PH domain interferes with the catalytic Sec7 domain (DiNitto
et al., 2007). Arf6-GTP binds to the PH domain of ARNO and
stimulates, in synergy with plasma membrane lipids, the nucleotide
exchange activity of ARNO on Arf1 (Cohen et al., 2007b; Stalder
et al., 2011). We found that Arf6-GTP binds to the PH-C-terminal
region of EFA6 (Padovani et al., 2014). Thus, by analogy with
ARNO, one could speculate that Arf6-GTP, by binding to the PH
domain of EFA6, could release the C-terminus and allow for
ACTN1 binding.
We had previously reported that EFA6A is present at and
regulates the TJ (Luton et al., 2004; Théard et al., 2010), where we
now find ACTN1. Our results support the hypothesis that it is
EFA6A that recruits ACTN1. The re-localization experiments
performed in the presence of Latrunculin B indicate that the binding
between EFA6A and ACTN1 is independent of F-actin. However,
F-actin is found around the mitochondria together with
EFA6ACter–ActA and ACTN1 suggesting that the EFA6A and
ACTN1 couple could organize actin filament structures or even
contribute to their nucleation, as proposed for ACTN4 at the AJ
(Tang and Brieher, 2012). ARNO was also found to bind directly to
ACTN1, through its C-terminal extremity, to modulate neurite
extension, suggesting that ACTNs could be a general player in the
Arf-regulated actin cytoskeleton (Torii et al., 2012).
Since EFA6A recruits ACTN1, we hypothesized that ACTN1
was acting as its effector. In the past, studying monolayers of
MDCK cells, we had found that overexpression of EFA6A
accelerates the general program of epithelial polarization,
including the assembly of functional TJs (Klein et al., 2008;
Luton et al., 2004). Part of the contribution of EFA6A has been
attributed to its ability to stabilize the PAMR. Here, by using a 3D
cell culture system together with siRNA-mediated depletion, we
show that EFA6A is necessary for normal luminogenesis in MDCK
cells. Conversely, overexpression of EFA6A increased the
proportion of cysts with a SCL and stimulated their enlargement.
Thus, we asked whether ACTN1 was acting as an effector to
transduce some of the effects of EFA6A on luminogenesis. Indeed,
we observed that depletion of ACTN1 blocked the stimulatory effect
of EFA6A on both the formation and enlargement of the round SCL.
In further support of this idea, depletion of ACTN1 had no
additional disruptive impact on cells knocked down for EFA6A.
This addition, expression of a mutant of EFA6A deleted of its
C-terminus, which contains the ACTN1-binding site, impaired
normal luminogenesis. These results demonstrate that ACTN1 is a
crucial effector of EFA6A whose function is to promote normal
luminogenesis.
To understand the roles of ACTN1, we analyzed in detail the
defects induced upon its depletion. In the absence of ACTN1, there
was an increase in cysts with multiple lumens, mostly as mini-
lumens formed between two cells, or cysts with lumens that failed to
extend to all cells. We propose that, in the absence of ACTN1, the
initial fusion event to form a PAP is facilitated; however, the
subsequent coalescence and extension of lumens to all cells of
the aggregate is precluded. In addition, the volumetric growth of
the lumens is impaired. In the ACTN1 knockdown cells, the mini-
lumens appeared to be essentially blocked at the PAP stage and, in
larger cysts, the extended lumens and SCL adopted an octopus-like
shape rather than a nice round hollow. Interestingly, in both MDCK
and MCF7 cells, in the absence of ACTN1, EFA6 overexpression is
capable of rescuing enlargement of the mini-lumens. However, at
later stages EFA6A overexpression cannot rescue the enlargement
because ACTN1 is required as an effector downstream of EFA6.
This implies that the enlargement of the luminal space relies on
different molecular machinery at different stages along the process
of lumen formation. Thus, ACTN1 is dispensable at the initial stage
to create the nascent lumens, but it is essential downstream
of EFA6A at later stages for the coalescence, extension and
enlargement of the lumens.
ACTN1 is an actin-bundling protein known to regulate the
contractility and stiffness of acto-myosin. It competes with myosin-
II to bind F-actin in order to maintain a complementary periodicity,
which results in linear F-actin bundles with contractile properties.
The ratio and distribution of these two proteins determines the
overall contractility and rigidity of F-actin cytoskeletons, including
that of the PARM (Arnold et al., 2017; Ferrari et al., 2008;
Sluysmans et al., 2017). Thus, ACTN1 could act by regulating
tension forces at the surface of the developing lumen. Several
observations support of this hypothesis. First, EFA6A and ACTN1
depletion reduced the amount of apical pMLC, whereas EFA6A
expression stimulated its accumulation at the apical pole in an
ACTN1-dependent manner. Second, upon ACTN1 depletion in
both MDCK and MCF7 cells, we observed two defects: (1) a
stimulatory effect on the initial formation of lumens as indicated by
the rapid accumulation of multiple mini-lumens and, (2) at later
stages, a defect of maturation (coalescence and extension) that leads
to large cysts with several lumens or incomplete lumens. These
results are consistent with a role for ACTN1 on contractility or
stiffness. Indeed, several independent studies have shown that
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decreasing contractility through treatment with blebbistatin, ROCK
inhibitors, or downregulation of LKB1 (also known as STK11), an
upstream regulator of RhoA, stimulates the initial formation of a
lumen at the two-cell stage (Cohen et al., 2007a; Ferrari et al., 2008;
Rodríguez-Fraticelli et al., 2012; Taniguchi et al., 2015). Less
appreciated is the impact of contractility at later stages. We found
that similar to what is seen upon ACTN1 depletion, blebbistatin
leads to large cysts with multiple lumens (our unpublished results).
A similar observation was made by reducing contractility through
depletion of LKB1, which first stimulates the initial formation of
lumens but then prevents their coalescence into a SCL (Rodríguez-
Fraticelli et al., 2012). Third, supplemental evidence for the role of
ACTN1 on contractility came from its effects in RhoAV14-
expressing cells. The small G protein RhoA, through its action
on the apical PAMR, is a general regulator of the assembly and
maintenance of the AJ (Lecuit and Yap, 2015) and TJ (Terry et al.,
2010). We showed that ACTN1-depletion could counterbalance
the RhoAV14-mediated contractility. We also found that
ACTN1-depletion rescued the initial formation of lumens
inhibited by RhoAV14 expression. Taken together, these results
indicate that luminogenesis is regulated by acto-myosin
contractility and stiffness, which should be kept low for the
initial formation of a mini-lumen, and then be increased to allow
for their coalescence and extension to form a SCL in larger
multicellular aggregates.
The implementation of tension forces relies on molecular pickets,
which are usually transmembrane proteins that anchor the acto-
myosin structures. In polarized epithelial cells, the AJ and TJ are
anchor points for the PAMR. It is noteworthy that neither EFA6A
nor ACTN1 appeared to be essential for the assembly and
positioning of the AJ and TJ, nor the establishment and
maintenance of the asymmetry along the apico-basal axis. Thus,
EFA6A and its effector ACTN1 modulate the contractility by
affecting the activity and/or organization of the apical acto-myosin
cytoskeleton and not the anchoring junctional complexes.
Not all the functions of ACTN1 appeared to be mediated through
regulating contractility. ACTN1 depletion prevented the luminal
enlargement, while the inhibition of contractility by inhibiting
myosin-II or LKB1 depletion (Rodríguez-Fraticelli et al., 2012) did
not affect the luminal enlargement. Enlargement has been proposed
to depend on apical membrane transport involving the delivery of
highly charged molecules, hydrostatic pressure mediated by ion
channels and coalescence of multilumens. In ACTN1-depleted
cells, the surface of the apical membrane appears large enough to
accommodate a bigger luminal volume. In addition, the highly
charged PDX protein is properly delivered and coalescence is not
relevant when considering SCLs with an octopus-like shape.
However, ACTN1 could help to retain polycystins, which are
implicated in intercellular mechanotransduction (Li et al.,
2005); Wilson, 2001), as well as ion channels. In fact, many ion
channels have been shown to bind or to require ACTNs in order for
them to be retained at the cell surface (Cukovic et al., 2001; Lu
et al., 2009; Maruoka et al., 2000; Sadeghi et al., 2002; Schnizler
et al., 2009; Wyszynski et al., 1997; Ziane et al., 2010). EFA6A
was also shown to bind the ion channels TWIK1 and Kir3.4
(Decressac et al., 2004; Gong et al., 2007). Furthermore, it has been
reported that ACTN4 regulates the outwards water transport in a
process called regulatory volume decrease in response to osmotic
swelling (Ando-Akatsuka et al., 2012). In summary, together with
EFA6A, the recruitment of ACTN1 to the apical surface might help
stabilize ion channels regulating fluid influx and consequently
lumen enlargement.
Alternatively, ACTN1 could serve to organize a non-contractile
scaffold to help support the spherical architecture of the luminal
membrane. To do so, ACTN1 could participate by bundling F-actin
filaments into rigid structures and/or could serve to link or even
nucleate actin filaments at the AJ or TJ to anchor the luminal actin
cytoskeleton. Such a role has been proposed for ACTN4 at the level
of the AJ (Tang and Brieher, 2012).
Finally, we examined the role of ACTN1 in the human tumoral
mammary cell lineMCF7.When grown in 3D culture, these cells fail
to assemble TJ, form a lumen or polarize (Han et al., 2010; Kenny
et al., 2007; Zangari et al., 2014). Only a small fraction of cell
aggregates display one or several mini-lumens. As shown in the past,
EFA6B expression stimulated the formation of extended lumens and
restored an epithelial-like phenotype. So, in contrast to MDCK cells,
the formation of extended lumens in MCF7 is strictly dependent on
the expression of VSV-G–EFA6B. Thus, these cells make a good
model to study the role of ACTN1 downstream of EFA6B. Indeed,
ACTN1 depletion totally blocked lumen formation, demonstrating
that ACTN1 is a crucial effector for EFA6B in the induction of
luminogenesis. Furthermore, ACTN1-depletion in wild-type MCF7
cells stimulated the formation of multiple mini-lumens that were
blocked at the PAP stage. EFA6B expression did not rescue the
formation of extended lumens but did enlarge their volume. Thus, in
agreement with our observations in MDCK cells, ACTN1 depletion
favors the initial formation of lumens in between two cells but
prevents their coalescence and enlargement.
In conclusion, we show that ACTN1 is an effector of EFA6A and
EFA6B to promote luminogenesis in normal and tumoral cell
models. We propose a scenario whereby, at the onset of
luminogenesis, the acto-myosin contractility and rigidity must be
kept low to relax the sub-membranous actin cytoskeleton where
vesicle fusion occurs at the AMIS. At this stage, EFA6 proteins have
a stimulatory effect on the formation and the enlargement of the
mini-lumens suggesting that it acts through an effector other than
ACTN1; perhaps through Arf6, which has already been shown to be
involved in luminogensis (Tushir et al., 2010; Zangari et al., 2014).
At a later stage, EFA6 proteins recruit ACTN1 to contribute to the
coalescence of the mini-lumens, their extension to neighboring
cells and enlargement.We do not exclude the possibility that EFA6
proteins could recruit other effectors to mediate its effects.
Nevertheless, ACTN1 is certainly a primary effector that might
act by modulating the contractility of the acto-myosin ring and
thereby mediating its effects on coalescence and extension (by
helping to pull the lumens together and breaking through the
junctional complexes). Given these results, the EFA6A–ACTN1
pathway might be important for tubulogenesis occurring through
the cord hollowing mechanism, where multiple mini-lumens
are formed along the tubular structure and subsequently fuse
to coalesce in a single lumen, in a ROCK–myosin II-dependent
manner (Bernascone et al., 2017; Kim et al., 2015;
Sigurbjörnsdóttir et al., 2014).
In summary, we identified and characterized the role of two new
regulators of luminogenesis: EFA6A and ACTN1. ACTN1 behaves
as an effector to transduce the stimulating effect of EFA6A on the
formation of a single and well-expanded central lumen by
facilitating the extension and enlargement stages. The EFA6A–
ACTN1 couple acts, at least in part, by balancing the contractility of
the cortical acto-myosin cytoskeleton. In the tumoral MCF7 cells,
this pathway has the capacity to restore the apico-basal polarization,
TJ assembly and collective cellular organization into a cyst with a
central lumen pointing to new directions for cancer research
and therapy.
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MATERIALS AND METHODS
Cells, media and transfection
BHK cells were grown in Glasgow’s minimum essential medium (GMEM;
Invitrogen, Paris, France) supplemented with 5% heat decomplemented fetal
calf serum (FCS; Biowest-Abcys, Nuaillé, France) and penicillin-
streptomycin (Invitrogen). Transient transfection was performed by
lipofection using JETPEI (Polyplus Transfection, Illkirck, France).
MDCK clone II cells expressing VSV-G–EFA6A, VSV-G–EFA6AΔC
(Luton et al., 2004) or Myc-RhoAV14 (Jou and Nelson, 1998) under the
control of the tetracycline-repressible transactivator were grown in MEM
(Sigma-Aldrich, Saint-Quentin-Fallavier, France), 5% decomplemented
FCS (Biowest-Abcys), penicillin-streptomycin and 20 ng/ml doxycycline.
Expression of EFA6A and RhoAV14 was induced upon removal of
doxycycline. Plasmids and siRNA transfections were performed by
nucleofection (Nucleofector™; Lonza, Köln, Germany). For stable
expression of ACTN1–GFP, ACTN4–GFP and ACTN1S744–GFP, the
cells were selected with geneticin (Invitrogen) 2 days after transfection.
MCF7 and MCF7-VSV-G–EFA6B (Zangari et al., 2014) were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) containing
10% decomplemented FCS (Hyclone™, GE Healthcare, France),
supplemented with insulin, transferrin, selenium, glutamine, sodium
pyruvate,MEMnon-essential amino-acids and penicillin-streptomycin (all
from Invitrogen). Transient transfection was performed by nucleofection.
For 3D cell culture, 104 cells were mixed with 20 µl of 5 mg/ml Matrigel
(BDBiosciences, Le Pont de Claix, France) deposited as a drop on a 12 mm
glass coverslip. The BHK and MCF7 cells were obtained from the ATCC
and authenticated by short tandem repeat profiling by the vendor. The
parental MDCK II cell line was from Dr Keith Mostov (University of
California, San Francisco, USA). MDCK and derived cell lines were tested
for species specificity. Newly thawed cells from frozen stocks were tested
for absence of mycoplasma contamination and used for 10 passages before
replacement.
Antibodies and reagents
Rabbit polyclonal sera specific for EFA6B (HPA034722; Sigma-
Aldrich), occludin (71-1500, Invitrogen), phosphorylated (Thr18/Ser19)
myosin light chain 2 (3674, Cell Signaling Technology, Leiden, The
Netherlands), the PI3K p85 regulatory subunit (ABS234, Millipore,
Molsheim, France), Hsp60 (Ab46798, Abcam, Paris, France), GST (27-
4577-01, GE Healthcare) were used. Mouse monoclonal antibodies
specific for gp135/podocalyxin (3B8; gift from George Ojakian, State
University of New York Downstate Medical Center), the VSV-G tag
(P5D4; Roche Diagnostics, Mannheim, Germany), actin (AC-40; Sigma-
Aldrich), E-cadherin (36; Invitrogen), paxillin (610052, BD
Biosciences), the 6× histidine tag (HIS1; Sigma-Aldrich), the Myc tag
(9E10 and rat hybridoma 3F10; Roche Diagnostics), GFP (7.1, Roche
Diagnostics), ACTN1 (BM75.2; Sigma-Aldrich and H-2; Santa Cruz
Biotechnology, Heidelberg, Germany) were used. The rabbit polyclonal
anti-EFA6A was as described elsewhere (Sakagami et al., 2007). The
horseradish peroxidase (HRP)-coupled and fluorescent probes
(secondary antibodies, phalloidin and DAPI) were from Jackson
ImmunoResearch Labs (Suffolk, UK) and Molecular Probes (Eugene,
Oregon, USA), respectively. Full details of antibodies, including
dilutions used are given in Table S1. All other reagents and chemicals
were from Sigma-Aldrich.
DNA constructs and siRNA
Constructs for the expression of the following proteins have been described
elsewhere: GFP–EFA6A (Decressac et al., 2004), mRFP–EFA6A (Théard
et al., 2010), GST–EFA6A, GST–EFA6ACter (Macia et al., 2008), (6xhis)–
EFA6A (Macia et al., 2008), βarrestin1Cter–GFP (Scott et al., 2002),
the GST–ABD [amino acids (aa) 1–269], GST–SRD (aa 218–749) and
GST–CAMD (aa 713–887) fragments of ACTN1 (Fraley et al., 2003),
ACTN1–GFP (Rajfur et al., 2002), GST–ACTN4 (Khurana et al., 2011),
ACTN4–HA and ACTN4–GFP (Michaud et al., 2006). The GST–ACTN1
construct was prepared by PCR amplification of full-length ACTN1 from
pEGFP-ACTN1 and cloned into EcoR1 and Xho1 sites of the pGEX4T1
using the following primers:5′-GATCGATCGAATTCATGGACCA-
TTATGATTCTCAG-3′ and 5′-TGTATCACTCGAGTTAGAGGTCACT-
CTCGCCGTAC-3′. The siRNA #2225 insensitive ACTN1–GFP was ge-
nerated by introducing silent mutations at positions 2236, 2237 and 2238
(aa Ser744) using the QuikChange mutagenesis kit (Agilent Technologies,
Courtabœuf, France) using the following primers 5′-GCCAAGGGCATC-
TCGCAGGAGCAGATGAATG-3′ and 5′-CATTCATCTGCTCCTGCG-
AGATGCCCTTGGC-3′. The resulting plasmid was termed ACTN1S744–
GFP. Full-length EFA6A and EFA6ACter were cloned into mRFP-N1-
ActA (Benjamin et al., 2010) by PCR amplification at the EcoRI and SacII
sites. Primers used to amplify and clone the full-length EFA6A were 5′-
GATCGATCGAATTCGCCGCCACCATGCCTCTCAAGTCACCTGTG-
3′ and 5′-GATCGATCCCGCGGGGGCTTCCGCCGCCCACTGCC-3′,
and those for the EFA6ACter fragment were 5′-GATCGATCGAATTCG-
CCGCCACCATGTTCTCTGCGCCCCCCTTCC-3′ and 5′-GATCGAT-
CCCGCGGGGGCTTCCGCCGCCCACTGCC-3′. The resulting plasmids
were termed EFA6A–mRFP–ActA and EFA6ACter–mRFP–ActA.
The specific and control siRNAs were designed and obtained from
Eurogentec (Angers, France) and Sigma-Aldrich. The silencing efficiency
of several siRNAs per target was assessed by immunoblotting (Figs S3 and
S4). Knockdown of canine EFA6A and ACTN1 expression in MDCK cells
was carried out using the siRNA #2661 5′-CCUAUCAGAGGCGGAGC-
UA-3′ or #1440 5′-CUCUUUCAGUUGUGUGUUU-3′ and siRNA #2225
5′-GCAUCAGCCAGGAGCAAAU-3′ or #594 5′-GGACGACCCACUC-
ACAAAU-3′, respectively. Knockdown of human ACTN1 expression in
MCF7 cells was carried out using the siRNA #1789 5′-
CCUCAGGAGAUCAAUGGCAAA-3′. Silencing specificity was verified
with control siRNAs, rescue experiments (Fig. 3C and Fig. 4B) and
additional independent siRNA (Fig. S4).
Recombinant proteins, pull-down assay and
immunoprecipitation
The induction and purification of GST constructs with glutathione–
sepharose CL-4B beads (GE Healthcare) was as previously described
(Macia et al., 2008). The N-terminal 6×his–EFA6Awas purified on Ni-NTA
columns according to the manufacturer’s instructions (Qiagen, Courtabœuf,
France). For the GST-EFA6A pull-down from cell lysates, MDCK-
ACTN1–GFP cells were lysed at 4°C in 0.5% Nonidet P-40, 20 mM
Hepes pH 7.4, 125 mM NaCl, 1 mM phenylmethylsulphonyl fluoride
(PMSF) and a cocktail of protease inhibitors (Complete™, Roche
Diagnostics). The cleared lysates were incubated for 4 h at 4°C with
1.5 µM of the indicated GST-fused proteins and 30 µl of glutathione-
sepharose CL-4B beads. After three washes in lysis buffer, the beads were
boiled in Laemmli buffer, submitted to SDS-PAGE and the proteins
revealed by immunoblotting. For the GST pull-down of purified His–
EFA6A, 10 µM of the indicated GST fusion proteins and 10 µM of His–
EFA6Awere incubated together for 2 h at 4°C, and the experiments carried
on as described above. For all GST pulldown experiments, an aliquot of the
mixture was analyzed by SDS-PAGE followed by immunoblotting to
estimate the total amount of the added proteins. For immunoprecipitation,
cells were solubilized in ice-cold Triton X-100 lysis buffer (1% Triton X-
100, 150 mM NaCl, 5 mM EDTA, 20 mM Triethanolamine-HCl pH 8.1
and 1 mM PMSF). After centrifugation for 20 min at 16,000 g at 4°C, the
supernatants were pre-cleared at 4°C for 10 min, centrifuged for 10 min at
16,000 g and combined with protein A–sepharose and the indicated
antibody overnight at 4°C. The beads were then washed three times in
washing buffer (1% Triton X-100, 0.2% SDS, 150 mMNaCl, 5 mMEDTA,
8% sucrose, 1 mM PMSF and the cocktail of protease inhibitors) and
washed once in washing buffer without detergent. The immunoprecipitates
were then resuspended and boiled for 5 min in Laemmli buffer before SDS-
PAGE and immunoblot analysis.
Immunoblotting
Samples were resolved on SDS-PAGE and proteins transferred onto a
nitrocellulose membrane.Membrane blocking (30 min at room temperature)
and antibody dilutions were performed in PBS with 5% non-fat dried milk.
The membranes were incubated overnight at 4°C with the indicated
antibody. The proteins were revealed by chemiluminescence (ECL,
Amersham, GE Healthcare) using secondary antibodies directly coupled
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to HRP. The membranes were analyzed with the luminescent image
analyzer LAS-3000 (Fujifilm, Saint-Quentin-en-Yvelines, France).
Immunofluorescence
Cells were fixed in 4% PFA, the samples processed as previously described
(Luton et al., 2004) and imaged on a confocal microscope (Leica TCS-SP5,
Nanterre, France and Zeiss LSM780, Marly-le-Roi, France). Images were
processed for presentation using NIH Image and Adobe® Photoshop® CS2
software.
Quantification of luminogenesis
Unless specified, all quantifications were from cysts of 4–15 cells obtained
after 48 to 72 h growth in Matrigel. Experiments were repeated at least three
times in triplicate and a minimum of 100 cysts per experimental replicate
were analyzed. Each cell aggregate was scanned by using confocal
microscopy to analyze the shape of the lumens and determine the
presence of a single lumen or multiple lumens. Cysts were classified
within five categories: cysts with a single central opened lumen (SCL), two
or more lumens regardless of their shape (multilumen), with an opened
lumen but that was not extended to all cells (incomplete lumen), with an
optically closed lumen (otherwise named pre-apical patch, PAP), and with
no lumen. Within the SCL class, we discriminated those lumens that were
well enlarged from those that were barely opened and not expanded
displaying an ‘octopus-like’ shape (see Fig. 3B). Note, that cysts with
dividing cells or with lumen-containing cells and/or nuclei were not
included. In addition, a separate quantification was performed for a lumen
opened only in between two cells (mini-lumen) as they fell in the
multilumen, incomplete and optically closed lumen categories (see Fig. 3E).
Enlargement refers to the increase of the luminal volume. When
enlargement was compromised there was an octopus-like lumen.
Extension refers to the opening of a lumen (in general starting in-between
two cells) to all the cells of the cell aggregate or coalescence of multiple
small lumens to eventually form a single lumen. When extension was
compromised it led to an incomplete lumen and/or to the presence of
multiple lumens including mini-lumens (see Fig. 3D,E).
Statistics
The experiments were performed at least three times in triplicate, and data
from all experiments were combined. Values are mean±s.d. Statistical
significance was calculated with a two-tailed Student’s t-test. Non-
significant difference (N.S.) are P>0.05; *P≤0.05; **P≤0.01; ***P≤0.001.
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